Lars Fruergaard Jorgensen, CEO of Novo Nordisk, told the Financial Times that Novo Nordisk is in talks with the healthcare system about an innovative pricing agreement for its weight loss drug Wegovy, as the company hopes to expand the use of obesity treatment by helping healthcare providers share years of costs.
He said that the company is willing to adopt a "flexible" attitude in its pricing plan, so that it can take medication in the early stage and pay fees in the later stage. He added, "We are open to the types of arrangements we can make with the healthcare system to help them provide services to the patients who need them the most."
However, although Eli Lilly plans to lower the listing price of its weight loss drug Zepbound by 20% compared to Wegovy, Jorgensen stated that Novo Nordisk has not yet planned to lower the price of the weight loss drug, but the company is willing to share the cost.